Opal Computational
Overview
Opal Computational Platform by Valo Health is an AI-driven drug discovery and development engine. It integrates large-scale human data, artificial intelligence, advanced causal inference techniques, and predictive chemistry. The platform is designed to identify new drug candidates, evaluate molecules, predict patient benefits, and optimize clinical trial design.
- What it does: Opal analyzes extensive human data, including genetic markers, to uncover associations between them and diseases. It then uses these insights to identify novel disease targets and rapidly engineer small molecules for therapeutic intervention. The platform also aims to predict drug safety and efficacy.
- Who it is for: Opal is primarily for pharmaceutical researchers and drug developers. Valo Health’s initial focus areas include cardiovascular diseases, neurodegeneration, and oncology.
- How it fits a clinical or practice workflow: Opal is intended to accelerate the drug discovery and development process, from target identification to preclinical candidates and clinical trial design. It aims to integrate human-centric data across the entire drug development lifecycle.
- Notable capabilities: The platform utilizes AI/machine learning, advanced causal inference techniques, and statistical genetics. It also incorporates a “closed-loop chemistry” system for rapid development of potential molecules and proprietary 3D engineered human tissue models for target validation. Opal has been used to identify patient subpopulations that may benefit most from early treatment in clinical studies.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-enabled human causal biology
- Closed-loop chemistry platform
- Leverages large-scale human data (17+ million de-identified patient records)
- Identifies novel disease targets
- Rapidly engineers novel small molecules
- Predictive confidence for clinical trial design and execution
- Integrated end-to-end drug discovery and development platform
- Proprietary 3D engineered human tissue models
- AI/ML, advanced causal inference techniques, and statistical genetics
- Cloud computing
Use Cases
- Drug discovery and development across major disease areas
- Identifying novel disease targets for therapeutic intervention
- Developing drug candidates for cardiovascular diseases, neurodegeneration, and cancer
- Evaluating new and known molecules to forecast interactions with protein targets
- Predicting which patients will benefit most from specific therapies
- Designing efficient clinical trials
Details
| Category | Drug Discovery & Research |
| Pricing | Unknown — unknown |
| Deployment | Cloud |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
Unknown AI-estimated Valo Health's focus is on drug discovery and development, aiming to bring more predictive confidence to clinical trial design and execution, and ultimately seeking FDA approval for new drugs. |
| Integrations | |
| EHR | Not specified |
| Specialties | Laboratory Medicine, Oncology, Pathology |
What the Web Says
Opal Computational, a platform by Valo Health, aims to accelerate drug discovery and development through AI and machine learning. Reviews suggest it is a powerful tool for researchers, particularly in early-stage drug discovery, by integrating diverse data types and providing predictive analytics. While praised for its potential to revolutionize the pharmaceutical industry, some sources highlight the complexity of its implementation and the steep learning curve for new users.
Overall: PositiveStrengths
- Accelerates drug discovery and development
- Integrates diverse data sources (genomic, clinical, real-world data)
- Utilizes AI/ML for predictive analytics and insights
- Potential to reduce costs and time in R&D
- Aids in identifying novel drug targets and biomarkers
- Strong scientific foundation and expertise within Valo Health
Limitations
- High cost of implementation and subscription
- Steep learning curve for non-specialist users
- Requires significant data integration and preparation efforts
- Limited public reviews from individual physicians or small clinics
- Potential for 'black box' issues with complex AI models
- Reliance on the quality and completeness of input data
Based on reviews from: Valo Health official website, Forbes, Fierce Biotech, Endpoints News, Crunchbase, LinkedIn (Valo Health employees and industry professionals), Industry analyst reports (general AI in pharma)
Last updated: 2026-08-24
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate Opal Computational
Press & Coverage
Valo Health Press Release
Valo Health and Novo Nordisk to collaborate to discover and develop novel treatments for cardiometabolic diseases using human data and artificial intelligence
Valo Health and Novo Nordisk announced a collaboration to discover and develop new treatments for cardiometabolic diseases using Valo's Opal Computational Platformu2122 and real-world patient data. Novo Nordisk licensed three preclinical drug discovery programs from Valo as part of the agreement.
2023-09
Fierce Biotech
Novo Nordisk pays $60M for 3 preclinical assets as part of AI-powered cardio collab with Valo - Fierce Biotech
Novo Nordisk is investing $60 million in Valo Health, acquiring rights to three preclinical drug discovery programs, to leverage Valo's AI-powered Opal Computational Platform for cardiovascular disease treatments. The deal includes potential milestone payments up to $2.7 billion for 11 programs.
2023-09
Taylor & Francis
Novo Nordisk signs agreement with Valo Health to use their AI drug discovery platform - Taylor & Francis
Novo Nordisk announced an agreement with Valo Health in September 2023 to utilize Valo's human datasets and AI-driven Opal Computational Platformu2122 for identifying and developing new cardiometabolic disease treatments. The deal is valued at $60 million and includes licensing three of Valo's preclinical drug-discovery programs.
2023-12
Valo Health Press Release
Valo Health and Novo Nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseases
Valo Health and Novo Nordisk expanded their collaboration to discover and develop up to 20 novel drug programs for obesity, type 2 diabetes, and cardiovascular disease, leveraging Valo's Opal Computational Platformu2122. The expanded agreement includes near-term payments totaling up to $190 million, with potential milestone payments of approximately $4.6 billion.
2025-01
PMLiVE
Novo Nordisk and Valo Health expand alliance for cardiometabolic diseases - PMLiVE
Novo Nordisk and Valo Health have expanded their agreement to develop new treatments for type 2 diabetes, obesity, and cardiovascular disease, with the deal now potentially worth $4.6 billion. The collaboration will continue to utilize Valo's AI-powered Opal computational platform.
2025-01
Valo Health Press Release
Valo Health and nference Announce Long-term Partnership to Accelerate Human-Centric Drug Discovery and Development
Valo Health and nference announced a multi-year collaboration to accelerate human-centric drug discovery and development by leveraging Valo's Opal Computational Platformu2122 with nference's Agentic AI platform and extensive de-identified patient data.
2025-03
Valo Health Press Release
Valo Health Announces Topline Results from Phase 2 SPECTRA Study of OPL-0401 in Patients with Diabetic Retinopathy
Valo Health announced topline results from its Phase 2 SPECTRA study of OPL-0401 for diabetic retinopathy, which did not meet primary or secondary endpoints but showed a favorable safety profile and some dose-related activity. Valo is seeking a partner for further development of OPL-0401 and will refocus on its Opal platform.
2024-12
Ophthalmology Management
Valo Health Suspends Development of Diabetic Retinopathy Drug
Valo Health has suspended the development of its diabetic retinopathy drug, OPL-0401, after its Phase 2 study did not meet primary or secondary endpoints, despite a good safety profile. The company will now seek a partner for the program and focus on leveraging its Opal platform for new drug discovery.
2025-01
Videos
Product demos, reviews, and walkthroughs for Opal Computational.
Loading videos...
Frequently Asked Questions
Opal Computational, developed by Valo Health, is an AI-powered, end-to-end drug discovery and development platform that integrates large-scale human data and machine learning. It aims to accelerate the identification and optimization of new therapeutics by analyzing clinical data to identify molecules and disease subpopulations, thereby cutting down time and cost in the drug discovery process.
Valo Health emphasizes the use of 'human-centric data' and 'de-identified patient data' within its Opal Computational Platform. Collaborations, such as with nference, leverage decades of comprehensive, HIPAA-compliant, fully de-identified patient-level data to enhance drug discovery and development. This focus on de-identified and compliant data is crucial for ethical and legal considerations in AI-driven medical research.
Yes, several other computational and AI-driven platforms exist in drug discovery. These include BIOVIA Discovery Studio, Chemical Computing Group's MOE, deepmirror, Optibrium's StarDrop, and Chemaxon's Plexus Suite. These alternatives offer various capabilities such as molecular modeling, cheminformatics, virtual screening, and lead optimization, often integrating machine learning and AI.
While powerful, computational approaches like Opal have limitations. Challenges include data quality, oversimplification of biological interactions in models, high computational resource demands, and difficulties in accurately representing complex biological systems. Additionally, AI output heavily depends on prompt clarity, and there can be challenges with real-time API or database integration in some experimental AI tools. Ethical concerns regarding data privacy, algorithmic fairness, and accountability also exist.
Specific pricing details for Valo Health's Opal Computational Platform are not publicly disclosed. However, Valo Health operates on a B2B business model, offering services and consulting, and potentially revenue-sharing agreements. Partnerships with larger entities like Novo Nordisk and Merck KGaA involve significant milestone payments and R&D funding, suggesting a substantial investment for access to the platform's capabilities. This implies that direct access for smaller research groups or academic institutions might be through collaborations or specific partnership models rather than a direct subscription service.
Suggest an Edit →
| Last Verified: 2026-08-23 | First Added: 2026-08-23
Investors who backed Opal Computational
Funded through the company that built this tool.
